X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

May 07, 2019

The Impact Poor Formulations Have on Drug Development Programs

<span>Before an injectable biologic can be formulated and manufactured, an extensive series of pre-formulation checks are necessary to ensure that developers avoid formulating an unstable, non-viable product&sup1;. Developers must determine whether the injectable biologic will break down within the intended formulation or the manufacturing process. The drug must be thermally stable, possibly resistant to oxidation, tolerate variations in light, and other environmental stresses placed on it during manufacturing and packaging.</span>
Victoria Morgan

Victoria Morgan

Director, Segment Marketing, Global Biologics

Previous Posts
Stoppers

April 23, 2019

Selecting the Right Package for a Drug Product

Page McAndrew

T. Page McAndrew

Director, Scientific Communications

Leo Posner of Johnson & Johnson presenting at the PDA Combo Workshop

April 03, 2019

The Challenges of Combination Products

Fran DeGrazio

Fran DeGrazio

VP, Technical Services and Scientific Affairs

Ready Pack System

March 12, 2019

Molecule to Market – Simplify the Journey™ for New Drug Products

Cathy Chhour

Cathy Chhour

Sr. Technical Account Specialist, TCS

PFS Syringe Systems

February 01, 2019

Challenges in Drug Containment and Delivery: How to Qualify Prefillable Solutions

Royce Brockett

Royce Brockett

Director, Product Management, Prefillable Systems

Prefillable Syringe Components

November 26, 2018

Addressing the Demands of Modern Drug Delivery Systems

Royce Brockett

Royce Brockett

Director, Product Management, PFS

Introducing Integrated Solutions

October 08, 2018

Introducing Integrated Solutions

Deirdre Swinden

Deirdre Swinden

Director, Marketing Communications

Daikyo D Sigma

October 05, 2018

A Culture of Innovation Sparks High-Quality Daikyo D Sigma® Elastomer Components

Piotr Wagner

Piotr Wagner Ph.D.

Sr. Specialist, Marketing, Product Management

Vial Adapters

October 01, 2018

Evaluating the Risk of Stopper Push-in by Spikes During Chemotherapy

Matthew Gehrmann

Matthew Gehrmann

Sr. Scientist, Scientific Communications, SA & TS

Load more